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Gene therapy (GT) for haemophilia is being evaluated for its potential 
to provide long-term, potentially curative treatment for people with 
haemophilia (PWH) by increasing endogenous clotting factor activity. 
This approach could replace the current standard of care, namely exog-
enous factor replacement that has undergone significant improvements 
over the last few decades but remains suboptimal in terms of preserving 
joint and overall health and is associated with a significant quality of life 
(QoL) burden. While GT has the potential to improve physical health 
and overall QoL, clinical experience is still relatively limited. This article 
provides perspectives from a haemophilia patient advocate, with per-
sonal experience of the disease, as well as physicians involved in clinical 
care regarding where GT might address unmet needs and mitigate the 
disease burden for PWH. It should be noted that due to limitations in 
the available evidence, some of the expert perspectives expressed in 
the manuscript will necessarily reflect personal experience and are yet 
unsupported by published peer-reviewed studies.
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The introduction of clotting factor therapy in the 1960s and 
1970s transformed life expectancy for severe haemophilia from 
under 30 years to near normal.1 The contamination of clotting 
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Gene therapy has the potential to revolutionise treatment for patients with haemophilia 
and is close to entering clinical practice. While factor concentrates have improved out-
comes, individuals still face a lifetime of injections, pain, progressive joint damage, the 
potential for inhibitor development and impaired quality of life. Recently published stud-
b;vbm-7;moŊ-vvo1b-|;7bu-ѴŐ(ő;1|ouŊl;7b-|;7];m;|_;u-r_-;7;lomv|u-|;7
improvement in endogenous factor levels over sustained periods, significant reduction 
in annualised bleed rates, lower exogenous factor usage and thus far a positive safety 
profile. In making the shared decision to proceed with gene therapy for haemophilia, 
physicians should make it clear that research is ongoing and that there are remaining 
evidence gaps, such as long-term safety profiles and duration of treatment effect. The 
eligibility criteria for gene therapy trials mean that key patient groups may be excluded, 
eg children/adolescents, those with liver or kidney dysfunction and those with a prior 
_bv|ouo==-1|oubm_b0b|ouvouru;Ŋ;bv|bm]m;|u-Ѵbvbm](-m|b0o7b;vĺ;m;|_;u-r
offers a life-changing opportunity for patients to reduce their bleeding risk while also re-
ducing or abrogating the need for exogenous factor administration. Given the expand-
ing evidence base, both physicians and patients will need sources of clear and reliable 
information to be able to discuss and judge the risks and benefits of treatment.
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factor concentrates (CFCs) prepared from pooled plasma with 
HIV and hepatitis viruses, however, blighted many lives.2 Safety 
improved with the introduction of effective viral inactivation 
l;-vu;v =oѴѴo;7 0 u;1ol0bm-m| 	 |;1_moѴo] bm |_;
1980s.2,3 Since then, CFCs have evolved with the development 
of extended half-life (EHL) versions that improve the QoL by re-
ducing dosing frequency4,5 and increase protection by enabling 
higher trough levels. Despite this, haemophilia continues to im-
pose multiple complications including joint damage, functional 
impairment, acute and chronic pain, mental health/anxiety is-
sues, reduced QoL, as well as impaired social participation, re-
duced educational attainment and diminished work productivity 
(Table 1).
ƐĺƒՊ|Պ&ml;|m;;7vbm_-;lor_bѴb-|u;-|l;m|
The limitations of current options highlight the need for less burden-
some and more cost-effective treatment that limits the longer-term 
complications experienced by PWH (Table 2). Preliminary evidence 
bm_-;lor_bѴb--m7bm7b1-|;v|_-|$l-o==;u|_;ro|;m|b-Ѵ|o
address these limitations.
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GT refers to the treatment of a disease through introducing a func-
tional copy of a disease-causing gene, inactivation of the gene's ef-
fects through addition of novel or modified genes, or editing of a 
host gene to correct a congenital mutation.6 GT strategies that are 
currently approved, or approaching approval, are largely aimed at 
treating diseases that are caused by a defect in a single gene, such as 
haemophilia, lipid disorders, retinal diseases and spinal muscular at-
rophy. The most common way to introduce therapeutic genes is via a 
viral vector. Unlike earlier approaches using adenoviral and retroviral 
vectors which insert the transgene into the genome of the host,7 re-
1ol0bm-m|-7;moŊ-vvo1b-|;7buv Őu(ő;1|ouv];m;u-ѴѴu;l-bm
in the nucleus of the transduced cell in non-integrated episomal 
1om1-|;l;u=oulŐ;1|ou	Ѵbmh;7_;-7|o|-bѴbm-1bu1Ѵ-u=oulőķ
b|_omѴ u-u;ķ u-m7ol bm|;]u-|bomv bm|o_ov|	ĺ8 This reduces 
|_;ro|;m|b-Ѵ=ou];mo|ob1b|b|_u(;1|ouv_;m1olr-u;7|o
insertional vectors. While such rare integrations do not appear to 
have been associated with clinical sequelae in animal models or clini-
cal studies, it should be remembered that the large number of vec-
tor genomes (vg) administered during a typical GT treatment means 
$     Ɛ Պ Burden of haemophilia
u7;m -v;
Joint damage Can result in chronic pain, disability and joint deformity at an early age 1,54,55
Poor health-related 
quality of life
Closely linked to the extent of joint damage 54
Functional 
impairment
More likely to suffer from arthropathy/arthritis, more likely to require knee/hip replacement compared with the general 
population.1,56 Poor mobility, self-care issues, and inability to perform usual daily activities 57,58
Social isolation Inability to participate in social or sporting activities 59
Pain Higher pain levels and functional impairment associated with anxiety, depression and unemployment.60,61 Pain/discomfort 
is an area where most individuals report experiencing extreme issues.54 Individuals may experience anger and frustra-
tion due to the pain, inconvenience and erratic nature of bleeds 62
Psychological mb;|ņ7;ru;vvbom-u;|_;-u;-v_;u;lov|bm7bb7-Ѵvu;rou|;r;ub;m1bm]ļ;|u;l;Ľbvv;v54
Personal 
productivity
7;uv;blr-1|om;71-|bom-Ѵ-1_b;;l;m|-m7ouhruo71|bb|7;|o-0v;m1;-m77b==b1Ѵ|b;v7;|o=m1|bom-Ѵ
impairments and pain 57,63,64
&ml;|m;;7 lr-1|
Treatment convenience Lifetime treatment, frequent injections.65,66 Prophylaxis is time-
consuming, contributing to poor adherence 67
Joint damage despite 
factor prophylaxis
Indicates that prophylaxis is failing to control some subclinical 
bleeding 55,68
Inhibitor development Occurs in approximately one-third of patients with severe hae-
lor_bѴb--m7ƺƔѷo=|_ov;b|__-;lor_bѴb--m7bm1u;-v;v
treatment cost and morbidity risks 69
High lifetime-treatment 
costs
High factor concentrate costs,1,70-72 means availability of factor 
prophylaxis is limited in many countries
Pain See Table 1
Limits on activity and 
social participation
See Table 1
$     Ƒ Պ Current unmet needs in 
haemophilia treatment
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that there is the potential for a large numbers of random integration 
events.
Safety concerns regarding initial GT studies using insertional 
vectors in the 1990s included the death of a patient following adeno-
viral therapy for ornithine transcarbamylase and multiple leukaemia 
cases following a retroviral therapy for severe combined immuno-
7;=b1b;m1-m7)bvho||ŊѴ7ub1_vm7uol;ĺ9-13ou; u;1;m|Ѵķ u(
vectors have been used most commonly as they effectively trans-
duce target cells but have a lower risk of immunogenicity compared 
with adenoviral vectors and have a low risk of genotoxicity versus 
insertional vectors.14(bvbm|;um-Ѵbv;7bm|o|-u];|1;ѴѴv00bm7bm]
to specific cell-surface receptors and is trafficked to the nucleus. In 
|_;m1Ѵ;vķ|_;(m1o-|v0u;Ѵ;-vbm]bu-Ѵ	=uol|_;1-rvb7
and the vector transgene is transcribed and expressed.8
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Several publications have provided in-depth reviews of the efficacy 
and safety of GT in haemophilia,15-17 so only brief coverage of thera-
pies in active development is included here.
Haemophilia A
$_;u; -u; v;;u-Ѵ 7;;Ѵorl;m|-Ѵ $ |ub-Ѵv =ou _-;lor_bѴb-  bm-
cluding valoctocogene roxaparvovec (BNM 270, Phase 3) at up to 
6 × 1013 vg/kg, SPK-8011 (Phase 1/2) at up to 2 × 1012]ņh]ķ*
ѶѶѶŐ_-v;ƐņƑő-|-mmv|-|;77ov;ķ(ƑņѶŊŊ(Ŋ(ƒŐ_-v;
1) at up to 6 × 1012]ņh]ķ"ŊƔƑƔŐ(Ŋ(ķ_-v;ƐņƑő-|-mm-
v|-|;7 7ov; -m7 +ƑƔƖƖƏƑƒ Ő(Ŋ_l-m  7ol-bmŊ7;rѴ;|;7
FVIII) at an unstated dose.18,19 In a trial of valoctocogene roxaparvo-
;1Ő(Ɣņ7ol-bmŊ7;rѴ;|;7_(őbmmbm;l;mķ|_;v;;mr-u|b1b-
pants in the high dose group (6 × 1013 vg/kg) achieved FVIII values 
above the 5 IU/dL cut-off for mild haemophilia for up to 52 weeks 
(range 19-164 IU/dL at 52 weeks).18 These levels were associated 
with a reduction in median annualised bleed rate from 16 to 1 with 
1;vv-|bombm|_;m;;7=ou(u;rѴ-1;l;m|0;;hƑƑŐ$-0Ѵ;ƒőĺ18.
Haemophilia B
ouv;;u-Ѵ_-;lor_bѴb-ķ(Ŋ0-v;7$bv0;bm]7;;Ѵor;7bm1Ѵ7-
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ƐŊ
_*1őķ -m7 om; bm ;-uѴ _-v; ƐņƑ Ő$ƐѶƏ-ő |_-| -u; v|-u|bm] |o
present early data on small numbers of participants with limited fol-
low-up.20-24m-77b|bomķ"Ŋ*ķ-bm1=bm];um1Ѵ;-v;|_-|bmv;u|v-
=m1|bom-Ѵ*];m;bm|o_;r-|o1|;vķbvu;1ub|bm]=our_-v;ƐŐ_||rv
://clini caltr ials.gov).
Vector-mediated GT in haemophilia B has demonstrated that it is 
rovvb0Ѵ;|o1om;u|r-|b;m|vb|_v;;u;7bv;-v;ŐƺƐѷ*-1|bb|ő|o
-ļlbѴ7Ľr_;mo|r;ķ|_-|bv;m7o];mov*Ѵ;;Ѵvo=Ɣѷoulou;b|_
;1|ouv |_-| 1-uubѴ7Ŋ|r; * v1_ -v $ŊƏѵƏ ou v1(ƑņѶŊ
ƐŊ_*1 Ő$-0Ѵ;ƒőĺ20-23 m-77b|bomķ$|bѴbvbm]bѴ7Ŋ|r;* bv
associated with the cessation of factor prophylaxis in most partic-
br-m|vķ |_; u;71|bom bm ;o];mov =-1|ou v-]; 0 ƕƒѷŊƖѵѷ -m7
-u;71|bom bm-mm-Ѵbv;70Ѵ;;7u-|;vo=0;|;;mƕƏѷ-m7ƖƓѷbm
|_ov;]uorv_o-1_b;;7l;-m*-1|bb|ƻƔѷĺ20,23
m ou7;u |o bm1u;-v; * ;ru;vvbomķ v;;u-Ѵ ]uorv _-; v;7
o|_;u-ub-m|vķv1_-v|_;m-|u-ѴѴo11uubm]*-7--ub-m|Ő;]
"ŊƖƏƏƐ-m7$ŊƏѵƐő-m7--ub-m|b|_-mo;ѴѴvbm;|o-u]bmbm;
v0v|b||bom-|rovb|bomƒƏƐŐ$ƐѶƏ-őķ_b1_;m_-m1;*-1|bb|
Ő$-0Ѵ;ƒőĺ)b|_|_;v;-rruo-1_;vķ*-1|bb|b;vbm|_;u-m];o=ƒƏѷ
|o ƻƓƏѷ _-; 0;;m u;rou|;7 -Ѵom]b|_ u;71|bomv bm -mm-Ѵbv;7
0Ѵ;;7v -m7 ;o];mov*v;o= -rruobl-|;Ѵ ƖƏѷ |oƐƏƏѷĺ m
addition, these variants may allow a lower dose of GT to be used, 
which may be useful if vector dose is a factor in the development of 
capsid-specific immune responses.
ƑĺƐĺƑՊ|Պ"-=;|
$_; v-=;| ruo=bѴ; o= ( ;1|ouv u;=Ѵ;1|v |_; =-1| |_; -u; u;-
Ѵ-|;7|om-|u-ѴѴo11uubm](ķ_b1_-u;];m;u-ѴѴmomŊr-|_o-
];mb1 bm _l-mvĺv _-v 0;;m 7bv1vv;7ķ u;1ol0bm-m|(omѴ
u-u;Ѵ bm|;]u-|;v bm|o _ov| 	ķ8 minimising the potential for 
genotoxicity.7 Based on relatively limited data from 35 partici-
pants, one of the main adverse events that was observed in 17 
o= ƒƔ r-u|b1br-m|v ŐƓѶĺѵѷő -1uovv -ѴѴ |ub-Ѵv -v |u-mvb;m| -Ѵ-mbm;
-lbmo|u-mv=;u-v; Ő$ő;Ѵ;-|bomv Ő$-0Ѵ;ƒőķ_b1__-v-Ѵvo0;;m
observed in previous GT trials utilising intramuscular injection.25 
)_bѴ;$;Ѵ;-|bomv-u;mo|-v-=;|bvv;r;uv;ķ-v|_;v;;;m|v
were generally asymptomatic and were treated with a course of 
corticosteroids, in some cases they have been associated with a 
reduction in factor activity (Table 3).18,20-23o;;u$;Ѵ;--
|bomvķ -Ѵom]b|_ouv; |_-m;r;1|;7*-1|bb|ķ26 resulted in 
|_;7bv1om|bm-|bomo=(u_ƐƏ*Ő	$*ƐƏƐő-1-m7b7-|;|_;u-r
=ou_-;lor_bѴb-ĺm_-;lor_bѴb-ķ$;Ѵ;-|bomv7b7mo|-rr;-u
|ou;=Ѵ;1||_;7ov;o=;1|ou-7lbmbv|;u;7b|_(ѶŊŊ_(Ŋ
V at 6 × 1011 vg/kg (n = 1 of 1) and 2 × 1012 vg/kg (n = 1 of 2), or 
with valoctocogene roxaparvovec (6 × 1012 to 6 × 1013 vg/kg). To 
7;-Ѵb|_$;Ѵ;-|bomvķ-|Ѵ;-v||_u;;|ub-Ѵvbm1Ѵ7bm]|_;-Ѵo1-
|o1o];m;uo-r-uo;1-m7"ŊѶƏƐƐ|ub-Ѵvbm_-;lor_bѴb--m7
the FLT180a trial in haemophilia B have used prophylactic ster-
oid treatment.18,24,27 Other treatment-emergent adverse events 
associated with GT include lethargy/fatigue,18,22 anaemia 21 and 
back pain (Table 3B).18 Long-term safety is uncertain as the length 
of follow-up in published studies is generally from 1 year up to a 
maximum of eight years.28,29 There are, however, positive safety 
reports from longer-term follow-up in animals.30.
ƑĺƑՊ|Պ&ml;|m;;7v
Recent years have seen a major expansion in treatment options 
with the wider availability of EHL CFCs. EHL factors have allowed 
a greater bleed protection by enabling higher trough levels to be 
achieved and have reduced the frequency of intravenous (IV) in-
fusions. However, PWH treated with EHL CFCs continues to be 
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Study details
Name/description GO-8 Dose ranging 
study
Dose ranging & 
safety
Phase 1/2 Pre-existing anti-
(Ɣ-m|b0o7b;v
Phase 3 +ƑƔƖƖƏƑƒ
Ő	$*ƑƏƐő
u(b|_
improved liver 
tropism
NCT number NCT03001830 NCT03061201 NCT03370172 NCT03569891 NCT03520712 NCT03392974 NCT03588299 NCT03003533
Status Recruiting Recruiting Recruiting 1|b;ķmo|u;1ub|bm] Enrolling Enrolling Recruiting Recruiting
Therapy
Vector/transgene (ƑņѶŊŊ 
FVIII-V
(ƑņѵŊ_( (ѶŊ	ol-bmŊ
deleted factor 
VIII
(Ɣņ7ol-bmŊ7;-
pleted hFVIII
(Ɣņ7ol-bmŊ
depleted hFVIII
(Ɣņ7ol-bmŊ
depleted hFVIII
Not stated Not stated
Study characteristics
Number of 
participants
18 20 10 9 10 40 18 12
Length of follow-up Up to 15 y Up to 3 y Up to 3 y 1 y Up to 5 y Up to 5 y Up to 5 y 1 y
Design Phase 1 Phase 1/2 Phase 1/2 Phase 1/2 Phase 1/2 Phase 3 Phase 1/2 Phase 1/2
Dose, vg/kg 6 × 1011 
2 × 1012 
6 × 1012
Not stated Not stated 6 × 1012 (Co. 1, n = 1) 
2×1013 (Co. 2, n = 1) 
6 × 1013 (Co. 3, n = 7)
6 × 1013 4 × 1013 Not stated 6 × 1011 (n = 2) 
1 × 1012 (n = 3) 
2 × 1012 (n = 7)
Baseline characteristics
(-m7*-1|bb|ķ
&ņ7ouѷ
ƺƐ ƺƐ ƺƐ ƺƐ ƺƐ ƺƐ ƺƐ ƺƐ
Efficacy
m7o];mov*ou
FVIII activity
ƻƔ&ņ7Őƕķѵ
and 69 IU/dL) 
at 6 weeks, 
n = 3
TBC TBC ƺƐ&ņ7ŐoĺƐő 
2 IU/dL (Co. 2) 
19-164 IU/dL (Co. 3)
TBC TBC TBC ƐƒѷŊƓƖѷ
Reduction in an-
m-Ѵbv;7*ou(
v;ķѷ
TBC TBC TBC 9 (Co. 1) 
88 (Co. 2) 
99 (Co. 3)
TBC TBC TBC 97
Reduction in annual-
bv;70Ѵ;;7vķѷ
TBC TBC TBC Not reported (Co. 1) 
c (Co. 2) 
88 (Co. 3)
TBC TBC TBC 97
Safety
";ubovd TBC TBC TBC Progression of chronic 
arthropathy
TBC TBC TBC u-7;Ƒ$;Ѵ;--
tion, FVIII decline, 
IFN-γ production
ŐomD鸀n;vő
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$u;-|l;m|Ŋu;Ѵ-|;7 No Grade III or 
]u;-|;uv
TBC TBC $;Ѵ;-|bomvķ
arthralgia, back pain, 
fatigue, productive 
cough
TBC TBC TBC TBC
$;Ѵ;-|bomvѴ;-7bm]
to reduction/loss of 
*-1|bb|
Elevations in 
2/3, no loss of 
*-1|bb|
TBC TBC 1/8 TBC TBC TBC 2/12
ő-;lor_bѴb-Ĺ(];m;|_;u-rb|_bѴ7Ŋ|r;*
 $ŊƏѵƏƑƏ v1(ƑņѶŊƐŊ_*121,22- vhboƏƏƖ
Study details
Name/description Phase 1/2 Phase 1 Phase 1/2
NCT number NCT02396342 NCT00979238 NCT01687608
Status 1|b;ķmo|u;1ub|bm] 1|b;ķmo|u;1ub|bm] 1|b;ķmo|u;1ub|bm]
Therapy
Vector/transgene (Ɣņ1o7omŊor|blbv;7bѴ7Ŋ|r;_* (Ѷņ1o7omŊor|blbv;7bѴ7Ŋ|r;_* (Ѷņ*
Study characteristics
Number of participants 10 14 30
Length of follow-up 1 y (5-year follow-up in progress) Up to 3 y Up to 5 y
Design Phase 1/2 Phase 1 Phase 1/2
Dose, vg/kg 5 × 1012 (Co. 1, n = 5) 
2 × 1013 (Co. 2, n = 5)
2×1011(Co. 1, n = 2) 
6 × 1011 (Co. 2, n = 2) 
2 × 1012 (Co. 3, n = 2)
Not stated
Baseline characteristics
(-m7*-1|bb|ķ&ņ7 ƺƑb ƺƐ ƽƑ
Efficacy
m7o];mov*ou(-1|bb| 4.4 IU/dL (Co. 1) 
6.9 IU/dL (Co. 2)
ƐĺѶѷŐoĺƐő 
ƑĺƔѷŐoĺƑő 
ƔĺƐѷŐoĺƒő
TBC
!;71|bombm-mm-Ѵbv;7*ou(v;ķѷ 81 (Co. 1) 
73 (Co. 2)
92 (overall) 
96 (Co. 3)
TBC
!;71|bombm-mm-Ѵbv;70Ѵ;;7vķѷ 53 (Co. 1) 
70 (Co. 2)
90 (overall) 
94 (Co. 3)
TBC
ŐomD鸀n;vő
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 $ŊƏѵƏƑƏ v1(ƑņѶŊƐŊ_*121,22- vhboƏƏƖ
Safety
";ubovd $;Ѵ;-|bomo=lbѴ7eseverity (n = 2), self-
limiting fever (n = 1)
No TBC
$u;-|l;m|Ŋu;Ѵ-|;7 $;Ѵ;-|bomvŐƒņƐƏőķru;b-ŐƒņƐƏőķ-mb-
ety (2/10), palpitations (1/10), headache 
(1/10), prostatitis (1/10), rash (1/10)
$;Ѵ;-|bomvŐƓņѵbmoĺƒőķѴ;|_-u]ķ-m-;lb- TBC
$;Ѵ;-|bomvѴ;-7bm]|ou;71|bomņѴovvo=*-1|bb| 0/3 4/4 TBC
ő-;lor_bѴb-Ĺ(];m;|_;u-rb|_-7-*-ub-m|
 "ŊƖƏƏƐ23 (ƔŊ_*1oŊ-7-Ő$ŊƏѵƐő75 (ƔŊ_*1oŊ-7-Ő$ŊƏѵƐő76 $ƐѶƏ-24
Study details
Name/description Phase 1/2a 
Long-term safety & efficacy
Phase 2b 
Dose confirmation
Phase 3 
HOPE-B
Phase 1/2 
*Ŋ$
NCT number NCT03307980 NCT03489291 NCT03569891 NCT03369444
Status 1|b;ķmo|u;1ub|bm] Recruiting Recruiting Recruiting
Therapy
Vector/transgene (ņ*-7--ub-m| (Ɣņ*-7--ub-m| (Ɣņ*-7--ub-m| (ņ*vŊu]1_-m];-|
 position 301 variant
Study characteristics
No. participants 20 3 56 18
Length of follow-up *-1|bb|ŐƔő 
!ŐƔő 
*u;rѴ-1;l;m|ŐƔő 
vŐƔő
*-1|bb|Őѵhő 
!ŐƐő 
*u;rѴ-1;l;m|ŐƐő 
vŐƔő
*-1|bb|ŐƑѵhő 
!ŐƐő 
*u;rѴ-1;l;m|ŐƐő 
vŐƔő
26 wk
Design Phase 2 Phase 3 Phase 3 Phase 1/2
Dose, vg/kg 5 × 1011 2 × 1013 2 × 1013 4.5 × 1011 (n = 2, first enrolled 
patients)
Baseline characteristics
(-m7*-1|bb|ķ&ņ7 ƺƑ ƺƑ ƺƑ ƺƐouƐŊƑ
Efficacy
m7o];mov*ou(-1|bb| ƒƒĺƕѷ ƒƐѷ TBC ƻƓƏѷ
!;71|bombm-mm-Ѵbv;7*ou(
v;ķѷ
91-100 TBC TBC 100
!;71|bombm-mm-Ѵbv;70Ѵ;;7vķѷ 96 TBC TBC No spontaneous bleeds, 1 trau-
matic bleed
ŐomD鸀n;vő
$     ƒ Պ (Continued)
ՊՍՊ |ՊƕMIESBACH ET AL.
dependent on regular injections and must always be cognisant of the 
peaks and troughs of their factor levels in relation to their activity. 
It is also clear that the same disparity of access which we have seen 
with standard half-life CFCs continues with EHL factors. The 2018 
European Haemophilia Consortium (EHC) survey of 40 European 
countries,31 identified only 10 countries that always, or sometimes, 
had access to EHL CFCs, and there was practically no access in 
Eastern or Central European countries.
mo|_;u-7-m1;bm|u;-|l;m|_-v0;;m|_;7;;Ѵorl;m|o=_-
manised bispecific antibody technology, which by binding to both ac-
|b-|;7*-m7=-1|ou*1-mlblb1|_;-1|bomo=(Ő;lb1bl-0őĺ
"01|-m;ovŐ"ő;lb1bl-0|_;u-r=ou(7;=b1b;m1b|_-m7
b|_o|bm_b0b|ouv_-v0;;mѴb1;m1;70|_;	ķ32 which will offer a 
degree of freedom from fluctuating factor levels by conferring a con-
stant level of protection while also removing the burden of IV infu-
sion.33,34 The level of protection conferred appears to be in the range 
which will prevent most bleeds, but does not confer a normal or near-
normal level of protection, so treatment for breakthrough bleeds and 
surgery with FVIII clotting factor will continue to be required.
Expectations of GT have changed significantly over the previous 
=b;;-uv-v;_-;v;;m*;ru;vvbombm1u;-v;=uol-lo7;v|
ƓĺƓѷŊƕѷbm;-uѴ|ub-Ѵv20-22|oƒƒѷlou;u;1;m|Ѵķ23 with the current 
hope being sustained expression of factor level in the normal range. 
ou_-;lor_bѴb-ķ|_;-Ѵo1|o1o];m;uo-r-uo;1=uolbol-ubm
_-v 7;lomv|u-|;7 ;ru;vvbom bm |_; moul-Ѵ u-m]; ŐƻƔƏ &ņ7ő -|
52 weeks in 6 of the seven participants in the highest-dose group 
and monitoring continues to assess the duration of expression.18 
Crucially, normal factor levels should be sufficient to free PWH from 
any requirement for treatment with factor concentrates in all situa-
tions, including surgery.
CoreHEM used a modified Delphi decision-making process with 
a group of 49 experts including PWH, clinicians, researchers, reg-
ulators, health technology assessors, payers and drug developers 
to identify outcomes of most importance to PWH.35 CoreHEM 
identified factor level, duration of expression of factor level, impact 
on chronic pain, healthcare resource utilisation, impact on men-
|-Ѵ_;-Ѵ|_-m7=u;t;m1o=0Ѵ;;7v-v |_;h;o|1ol;vĺ =-1|ou
level in the normal range should transform the QoL of PWH. From 
a patient perspective, the duration of expression should ideally 
be lifelong but, if not, should be sustained over many years. With 
the current technology, re-treatment with the same vector is not 
possible, and in any case the economics of GT may not allow this. 
Chronic pain impacts most PWH due to a combination of target 
joints, pre-existing haemophilic arthropathy and subclinical bleeds. 
m;17o|-ѴѴķ |_;u; _-; 0;;m u;rou|v =uol r;orѴ; |u;-|;7 b|_
*ou " |_;u-r =ou( o= - vb]mb=b1-m| 7;1u;-v; bm fobm|
aches and pains. This may reflect higher trough levels, especially 
b|_*ķou_b]_;u;tb-Ѵ;m|Ѵ;;Ѵo=ruo|;1|bom1om=;uu;70
SC therapy for FVIII leading to a significant decrease in subclinical 
bleeds. Therefore, it will be of great interest to assess the long-term 
impact of GT on acute and chronic pain as well as the arthropathy, 
although, for those who already have end-stage arthropathy, the 
impact may be minimal.
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ѶՊ|ՊՊՍ MIESBACH ET AL.
Gene therapy with a factor expression in the normal range would 
free PWH from their mental burden and may lead to a real reduc-
tion in the levels of anxiety and depression.36 With greater levels 
of protection, the frequency of bleeds should decrease even in the 
presence of higher levels of physical activity. Freedom to carry out 
normal everyday activities, taken for granted by those without hae-
mophilia, such as walking, running, cycling, swimming and potentially 
riskier sports participation would all become more attainable.
ƒՊ |Պ)$	"&""$! +Ĺ
+"	$$!" $("
 +	"$ +
ƒĺƐՊ|Պ==b1-1
From a physician perspective, it will be key to manage patient expec-
tations of GT, particularly in the early days following treatment. GT 
has demonstrated the ability to convert individuals from a severe to 
mild phenotype in terms of endogenous factor activity; however, 
treated adults are likely to have a legacy of joint damage that may 
increase bleed risk even in the post-GT setting with normal or near-
normal endogenous factor activity. During the initial post-GT period, 
and depending on the attained factor level, physicians should advise 
individuals that GT should not be considered as cured, that they 
may continue to require clinical monitoring despite having mild hae-
mophilia, and that any increase in physical activity should be under-
taken cautiously. In trials to date there have been initial indications 
that the bleed risk diminishes with longer length of follow-up after 
GT,18,20 so it will be of interest to determine whether the presence of 
stable factor levels over the longer term can induce clinical improve-
ments in target joints and therefore reduce bleed risk.15 Changes 
in how individuals manage their haemophilia may cause stress or 
-mb;|ķvo;lo|bom-Ѵvrrou|l-0;m;;7;7ĺmo|_;u-vr;1||_-|
should become clearer with increasing experience is whether poten-
tial determinants of responses to GT such as the extent of joint dam-
age, presence of neutralising antibodies, potential markers of the 
likelihood of T-cell-mediated immune responses, or other currently 
unknown prognostic factors can be identified.
Patients are likely to be interested in how long they can expect 
the benefits of GT to persist. Within the limited follow-up of current 
|ub-Ѵvķ$=ou_-;lor_bѴb-_-vu;vѴ|;7bmv|-0Ѵ;*;ru;vvbom=ou
up to eight years,28,29 however, the longer-term durability of expres-
vbomu;l-bmv|o0;7;|;ulbm;7ĺb;m|_-| u;1ol0bm-m|(7o;v
not generally integrate into host genomes, levels of transduction are 
expected to fall as cells turnover and die.8,37 Under normal condi-
|bomvķlov|_;r-|o1|;v-u; bm-tb;v1;m|v|-|;b|_ƺƐѷŊƑѷm-
dergoing turnover at any time.38,39 While there is some uncertainty 
due to limited data, each non-resting hepatocyte has an estimated 
lifespan of 200-300 days, so it is likely that the documented sta-
0Ѵ;*Ѵ;;Ѵvu;=Ѵ;1| Ѵo_;r-|o1|;|umo;uĺ29,38 Patients should 
also be made aware of the fact that the apparent lack of clinically 
u;Ѵ;-m|bm|;]u-|bomo=|_;(;1|ou-Ѵvol;-mv|_-|-m0;m;=b|v
from GT will not be passed on to children. Therefore, following the 
initial meeting with their physician, individuals should write down 
any questions they have and ensure they are answered. They should 
decide what outcomes they would consider to be acceptable, in 
terms of factor activity, duration of factor expression and the po-
tential level of bleed reduction, while appreciating that there are still 
uncertainties in terms of the level and duration of factor expression. 
Given that GT is still in the investigational stage, however, individu-
als should be prepared for the possibility of a poor outcome (such as 
low expression, no expression or early loss of expression).
From a patient perspective, resource utilisation is important, 
particularly in those countries in which treatment costs are borne by 
the individual or treatment can be refused by health insurance com-
panies. They will reasonably expect the best treatment from their 
providers and strong advocacy from their representative patient or-
ganisations. For healthcare provided by a national health service or 
national insurance model, it is likely that an amortisation payment 
model, in which the initial treatment cost is spread by making pay-
ments over several years, may become the preferred model. This 
would be cost-effective, would not have an enormous budget impact 
in year one and could include an element of risk sharing if the contin-
ued payment was linked to continued factor expression at a defined 
level. It may be the case that GT becomes a more attractive option 
even for developing and emerging countries where the current high-
lifetime costs of CFC treatment are not seen as sustainable.
ƒĺƑՊ|Պ"-=;|
GT is a relatively new technology that is starting to enter clinical 
ru-1|b1;ĺv bv1Ѵ;-u =uol|_;ru;bovv;1|bomķ |_;1uu;m|1Ѵbmb1-Ѵ
evidence for GT in haemophilia reflects limited follow-up in a rela-
tively small number of PWH.18,20-23 Thus, when addressing ques-
tions about GT, physicians should be clear that there are areas of 
uncertainty, such as longer-term efficacy and safety, for which only 
further clinical experience will provide answers.
h;ouubv$v-=;|ķr-u|b1Ѵ-uѴ7;|o|_;v;ubovv-=;|
concerns in the early trials using integrating vectors.40 The majority 
o=1uu;m||ub-Ѵvv;(;1|ouvķ_b1_-u;l1_Ѵ;vvѴbh;Ѵ|obm|;-
grate into the host genome or cause malignant transformation com-
r-u;7b|_bm|;]u-|bm];1|ouvĺv7bv1vv;7bm|_;ru;bovv;1|bomķ
mol-fouv-=;|bvv;vb|_(Ŋl;7b-|;7$_-;0;;mb7;m|b=b;7ķ
although the current follow-up periods are relatively short. The nor-
l-Ѵu-m];o=*-m7(bmr;orѴ;b|_o|_-;lor_bѴb-bvƔƏѷ|o
ƐƔƏѷo=moul-Ѵķ_o;;uķ*-Ѵ;vƻƐƑƔѷ-m7(-Ѵ;vƻƐƏƏѷ
may be associated with increased thrombogenicity.40-42 There does 
mo|-rr;-u|o0;-mbvv;bm*];m;|u-mv=;uķ_b1_bv-vvo1b-|;7
b|_*-1|bb|-||_;Ѵo;uu-m];o=moul-Ѵĺm1om|u-v|ķ(];m;
|u-mv=;u_-v0;;m-vvo1b-|;7b|_(-1|bb|ƻƐƔƏѷo=moul-Ѵbm
some participants, which was not associated with thrombotic events 
based on a small number of participants with limited follow-up18; 
however, it makes sense to avoid inducing supraphysiologic levels 
of FVIII.
uol - ru-1|b1-Ѵ r;uvr;1|b;ķ ;1|ou 	 bv 7;|;1|-0Ѵ; bm
bodily fluids for variable periods ranging from 2-28 weeks in urine, 
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4-52 weeks in saliva, 4-56 weeks in semen, 16-52 weeks in faeces, 
-m7=uolƓ;;hv|oƻƐ;-ubm0Ѵoo7ĺ20 The detection of vector ge-
nome fragments does not indicate infectious risk as the test does not 
distinguish between infectious vector particles, and free, episomal, 
ou bm|;]u-|;7	ĺ lrou|-m|Ѵķ u;1ol0bm-m|(;1|ouv-u;7;-
signed so that they are unable to replicate. In non-human primates, 
while vector genome sequences were identified in different cell 
populations and tissues for up to 18 months, infectious vector parti-
cles were rapidly cleared within 72 hours.43 In other animal studies, 
vr;ul1;ѴѴv-rr;-u|o0;u;=u-1|ou|o(|u-mv71|bomķѴ;vv;mbm]
the risks of vertical transmission.44 However, while the risk of third-
party infection is limited, physicians should recommend barrier con-
traception for up to 12 months as a precaution.
From a patient perspective concerns may include the risk of mu-
tagenesis due to vectors insertional events (Table 4). Other concerns 
may include vector shedding and the risk of infecting family mem-
bers and close contacts. Patients may also be worried about whether 
GT may increase the risk of inhibitor induction. There may also be 
anxiety related to potential trade-offs between increasing the vec-
tor dose, the level of factor activity that can be achieved and safety.
ƒĺƒՊ|Պ ;v|bomvu;]-u7bm]|ub-Ѵr-u|b1br-|bom
In terms of the physician perspective, setting patient expectations, 
both for clinical trials and ultimately for gene therapy as an approved 
treatment option for haemophilia, will be important, as some PWH 
will not qualify for treatment. The standard inclusion/exclusion cri-
teria employed in clinical trials to date have limited participation to 
adult patients with severe or moderately severe haemophilia,33,36,37 
with exposure to factor treatment for defined periods of time 
ŐƾƔƏ7-vlbmbllbmr0Ѵbv_;7|ub-Ѵvőķ-m7=oulov| |ub-Ѵvķmoul-Ѵ
liver and kidney function including absence of liver fibrosis. Trials 
generally exclude those with inhibitors, which would include approx-
bl-|;Ѵom;Ŋ|_bu7o=r;orѴ;b|__-;lor_bѴb-ĺѴѴo=|_;r0Ѵbv_;7
r_-v;ƐņƑv|7b;v=ou_-;lor_bѴb--m7;1Ѵ7;7r-|b;m|vb|_
active hepatitis B or C (generally defined as active hepatitis antigen, 
	rovb|bb|ou!bu-ѴѴo-7rovb|bb|ő-m7-1|b;(bm=;1|bom
(generally defined as positive serological test for HIV plus a CD4 T-
1;ѴѴ1om|o=ƽƑƏƏr;uμL and detectable HIV viral load), although one 
study also excluded patients who were HIV positive.37 To date, all 
trials have also excluded patients with pre-existing antibodies to the 
(v;uo|r;vr;1b=b1|o;-1_o=|_;bm;v|b]-|bom-Ѵruo71|vĸ_o-
ever, at least one phase 3 trial for haemophilia B [NCT03569891] has 
lifted that exclusion criterion due to lack of evidence for associated 
reduced efficacy or immune responses due to pre-existing low-titre 
m;|u-Ѵbvbm]-m|b0o7b;v|o(Ɣĺ45 Exclusion of key populations such 
children and adolescents, women with haemophilia,46 and those 
with a history of inhibitors to factor replacement is consistent across 
Phase 1-3 haemophilia GT trials, but a GT trial in people with hae-
lor_bѴb--m7bm_b0b|ouv_-v0;;m-mmom1;7ĺ47 If GT does become 
available in children and adolescents, there may be ethical questions 
in terms of gaining informed consent. There has been an initial re-
port of an adverse event potentially associated with a concomitant 
anti-HIV drug,48 so if these kind of interactions are confirmed, care 
may need to be taken in treating some individuals with GT.
Beyond these factors, there are currently no characteristics that 
can be used to identify those who are likely to respond better or 
worse to GT, although this will likely become clearer as the evidence 
base grows. Importantly, the majority of newly approved treatments 
typically will likely gain indications specific to the populations stud-
ied in the clinical trials; thus, it will be important to set expectations 
for excluded populations on timeline of treatment availability and 
the necessity to gather evidence in these groups once GT becomes 
more established.
For patients who participate in clinical trials, there is a practical 
burden of frequent study visits in the short-term, as well as long-
term (5 years on average) follow-up, which may be underestimated 
0ro|;m|b-Ѵr-u|b1br-m|vĺ|rb1-Ѵ|ub-Ѵl-u;tbu;;;hѴour|o
tri-weekly visits in the first 6 months, monthly or quarterly visits up 
to 12 months and quarterly or bi-annual visits for the remaining fol-
low-up despite participants potentially having normal or near-normal 
factor levels. Participants will generally need to record factor use and 
bleeds using an e-diary or similar approach, which will then be re-
viewed at each visit. During visits, body fluid samples will be required 
for vector shedding analysis; blood will be required for determining 
=-1|ou -1|bb|ķ bm_b0b|ouvķ Ѵb;u ;ml;vķ -m|bŊ=-1|ou -m|b0o7b;vķ ou
(-m|b0o7b;vņm;|u-Ѵbvbm]-m|b0o7b;vķbm=Ѵ-ll-|oul-uh;uvķ$Ŋ1;ѴѴ
responses and other trial outcomes. Given that trials usually take place 
in specialist centres, study-related visits will likely involve travel and 
$     Ɠ Պ Typical questions PWH may have before deciding to 
enter a GT trial
 ;v|bom
Which trial should I participate in?
What are the results, if any, from earlier phases of the trial?
What is the reputation of the trial team?
What vector is being used and what is the prevalence of pre-existing 
vector antibodies?
Will pre-existing antibodies automatically rule out trial participation 
or have strategies been developed to address this issue?
What vector dose is being infused and what is the anticipated range 
of factor expression? Is a higher vector dose worthwhile if the 
objective is higher factor expression?
l1ol=ou|-0Ѵ;|-hbm]-ruor_Ѵ-1|b11ouv;o=v|;uob7vb=|_-|bv
part of the protocol?
What duration of transgene expression is expected? 
What is the lower limit of duration of expression which would be 
persuasive to you in agreeing to participate in a trial or treatment? 
While lifetime expression is desirable, would I agree to treatment if 
expression was for 10 y? What about 1 y?
)_-|bv|_;ro|;m|b-Ѵ=oubm|;]u-|bomb|_-m(;1|ouĵ)_-|bv
the likelihood of insertional mutagenesis and the risk of developing 
cancer in the future?
Is there a risk of inhibitor development?
l1ol=ou|-0Ѵ;b|_|_;7;]u;;o=lomb|oubm]-m71ollb|l;m|
required, especially in the first year, and with annual follow-up for 
up to 15 y?
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potentially overnight accommodation. Other potential logistical issues 
include limitations on travel, the need for abstinence from alcohol in 
some trials, and potentially limitations on physical exercise to avoid 
muscle-related transaminitis elevations. Even when GT is approved, it 
is likely that treated patients will need additional follow-up to confirm 
sustainable transgene expression, clinical efficacy and safety.
From a patient perspective, with so many trials recruiting and 
ongoing, it is worthwhile to review the key outcomes and the types 
o=t;v|bomv)lb]_|_-;Ő$-0Ѵ;Ɠőĺv7bv1vv;7bm|_;ru;bov
section, key outcomes for PWH include factor level, duration of fac-
tor expression, reduction in chronic pain, healthcare resource utilisa-
tion, impact on mental health and bleed frequency.35 Therefore, it is 
likely that individuals will choose to participate in trials based on the 
factors which are most important to them.
In an ideal scenario, the consent process should involve an in-
dependent person separate from the haemophilia treatment centre 
team who will clearly set out the potential risks to ensure full in-
formed consent; however, this is not a requirement for consent in 
most trials. When introducing trials to PWH, it makes sense for ini-
tial communications to take place in small groups as such meetings 
often develop into discussion forums, which prompts questions that 
some attendees may not have thought about. Individuals should also 
familiarise themselves with relevant information from their national, 
u;]bom-Ѵou]Ѵo0-Ѵ_-;lor_bѴb-r-|b;m|ou]-mbv-|bomvĺv$0;1ol;v
more established, it will be important for these organisations to pro-
vide patient friendly educational materials including video and to fa-
cilitate education sessions/lectures/conferences for their members. 
PWH should familiarise themselves with the trial protocol.
ƒĺƓՊ|Պ"ou1;vo=bm=oul-|bomom];m;|_;u-r
Given the gaps in the evidence base, it will be important to em-
brace a shared decision-making approach.49 Physicians should 
give patients a clear understanding of the benefits and risks of 
GT based on the best available evidence at the time to enable a 
collaborative decision on the best treatment choice based on an 
individual's clinical history, preferences and treatment goals.49v
discussed below, patient organisations are also likely to be an im-
portant source of information. Connecting prospective trial par-
ticipants with those who have received GT will also be invaluable, 
particularly in terms of the practicalities of treatment administra-
tion and what to expect following treatment. This peer mentoring 
approach could be facilitated locally on a centre-by-centre basis or 
by patient organisations.
There are currently limited sources of high-quality, indepen-
dent information on GT. The National Hemophilia Foundation 
includes brief patient-focused information on GT (https ://www.
hemop hilia.org/Bleed ing-Disor ders/Future-Thera pies) and details 
a free telephone number that can provide more information on 
novel therapies. The EHC (www.ehc.eu) launched a provider-fo-
cused educational activity in collaboration with Medscape and a 
Novel Products newsletter that will be updated on a regular basis 
which covers GT in some detail.50 The EHC has released a series 
of five educational videos on GT designed for PWH. The World 
Federation of Hemophilia (https ://www.wfh.org) has an online 
video covering several new treatment options including GT ap-
ruo-1_;vĺ $_; l;ub1-m "o1b;| o= ;m; -m7 ;ѴѴ $_;u-r _-v
two online webinars aimed at PWH, which provide an overview 
of GT in general and the role of GT in haemophilia (https ://www.
asgct.org/meeti ngs-works hops/upcom ing-webin ars/hemop hil-
b-Ŋ;0bm-uvőĺ$_;-|bom-Ѵu]-mb-|bom =ou!-u;	bv;-v;v Ő_||rv
://rared iseas es.org/rare-disea ses/hemop hilia-b/) has information 
on earlier GT trials.21,22 Therefore, there is a need to provide a 
centralised, accessible and unbiased information source, so that 
PWH can access clear and easy to understand information on the 
novel therapeutic options in haemophilia.
ƒĺƔՊ|Պ$_;=|u;o=_-;lor_bѴb-];m;|_;u-r
It is an exciting time in GT, when the long-heralded promise is start-
ing to yield treatments that are entering the clinic. Most ongoing 
haemophilia GT trials utilise the process of gene addition, that is, 
bm=vbm]-_;-Ѵ|_1oro=-1Ѵo||bm] =-1|ou];m; Ő(ou *őb--m
(;1|oubm|o-r-|b;m|b|_o|-Ѵ|;ubm]|_;buom	ĺ$_;u;bv
at least one trial exploring gene editing for haemophilia, a process 
0_b1_-bm1=bm];um1Ѵ;-v;Ővol;|bl;vu;=;uu;7|o-vļ	v1bv-
sors) is used to insert the therapeutic transgene into a so-called safe 
harbour or area with high-transcriptional activity.51 Other types of 
GT are also being explored and it will be important for physicians to 
educate patients and families on the different options and discuss 
which approaches meet individual needs. It is likely that when GT ini-
tially become available that they will be prescribed through a limited 
number of expert centres, which should be fully able to discuss and 
educate patients about treatment options.
v_-;lor_bѴb-$;m|;uv|_;1Ѵbmb1-m7bvv0f;1||ovu;bѴѴ-m1;ķ
the longer-term safety and efficacy profiles will become clearer. 
Theoretically, at least, it would make sense to initiate GT before 
joint damage is manifest, which may start between 1 and 2 years of 
age.52 While current trials in haemophilia are confined to adults, as 
the safety profile of GTs becomes more established, it will be im-
portant to include adolescents and children, so that treatments can 
be opened up to this important population. Treatment in younger 
populations, however, may present additional challenges in terms 
of the potential impacts of hormonal and developmental changes as 
well as liver growth on long-term GT effectiveness. The development 
of inhibitors is a major problem that limits clotting factor treatment 
options and efficacy, so it will also be of great interest whether GT, 
either alone or when combined with other approaches such as im-
mune tolerance induction, can benefit such patients, and the future 
u;vѴ|v=uol|_;u;1;m|Ѵ-mmom1;7$|ub-Ѵbm_-;lor_bѴb-b|_
inhibitors will be awaited with interest.47ml0;uo=7b==;u;m|-r-
proaches have been studied in animals including classical immune 
tolerance induction with repeated exposure to antigens to therapies 
specifically targeting T or B cells.53
While the treatment of haemophilia has improved, it is costly 
and burdensome. Despite CFC, haemophilia still has major adverse 
ՊՍՊ |ՊƐƐMIESBACH ET AL.
impacts on the QoL of PWH including functional impairment, pain, 
and psychosocial issues. Longer-term evidence is needed to confirm 
whether haemophilia GT offers durable efficacy precluding the need 
for factor replacement. Experience from clinical trials so far suggests 
that it offers a life-changing opportunity for PWH to reduce their 
bleeding risk while also reducing or abrogating the need for exoge-
nous factor administration.
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